A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and Either Normal or Elevated Triglycerides.
Sponsor: Esperion Therapeutics, Inc.
A PHASE2 clinical study on Dyslipidemia, this trial is completed. The trial is conducted by Esperion Therapeutics, Inc. and has accumulated 9 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Feb 2021 — Apr 2021 [monthly]
Completed PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Apr 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Apr 2019 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Dec 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Esperion Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .